Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases
{{output}}
Background: The INDIGO trial recently showed that vorasidenib improves progression-free survival in patients with grade 2 IDH-mutated glioma. However, 20%-25% of patients experienced disease progression within the first year, ref... ...